The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2022 | New research areas in the treatment of AML
Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, explains the areas of excitement in acute myeloid leukemia (AML) research. Important advances have occurred when AML has been broken down into subsets of molecularly similar groups. For example, a subset of AML, acute promyelocytic leukemia (APL), can be treated with ATRA and arsenic. Dr Pemmaraju then highlights other key areas and their role in the future treatment of AML, and the importance of immunotherapies and combination therapies.This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
